Reid Hooper

Cooley advised Perceptive Advisors, a top healthcare investment firm, and its affiliates, including Perceptive Discovery Fund, on its definitive merger agreement with Vapotherm, a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, and listed as VAPO on the over-the-counter quotation exchange (OTCQX).

Cooley advised Structure Therapeutics (Nasdaq: GPCR), a global, clinical-stage biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, on its upsized $547.4 million underwritten public offering.

Cooley advised Life360, a family connection and safety company, on its $178.5 million initial public offering.

Cooley advised Lexeo Therapeutics, a clinical-stage gene therapy company advancing gene therapy candidates for genetically defined cardiovascular diseases and a genetically defined subgroup of Alzheimer’s disease, on its approximately $100 million initial public offering.

Cooley advised Abivax, a clinical-stage biotech company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering.